Skip to main content

Advertisement

Table 1 Failed phase 3 trials on anti-amyloid therapy in AD since 2016

From: Clinical trials of new drugs for Alzheimer disease

YearDrugMechanism of actionParticipantsMain reasons for failureRemarks
2016SolanezumabMonoclonal antibodyMild ADLack of efficacy 
 SolanezumabMonoclonal antibodyProdromal ADStrategic 
 VerubecestatBACE inhibitorMild to moderate ADLack of efficacy 
2018VerubecestatBACE inhibitorProdromal ADLack of efficacyWorsens cognition
 AtabecestatBACE inhibitorPreclinical ADToxicityWorsens cognition
 LanabecestatBACE inhibitorEarly ADLack of efficacyWorsens cognition
 LanabecestatBACE inhibitorMild ADLack of efficacyWorsens cognition
2019AducanumabMonoclonal antibodyEarly ADLack of efficacy 
 CNP520BACE inhibitorPreclinical ADLack of efficacyWorsens cognition